Inactivation of human T-cell lymphotropic retrovirus (HTLV-III) by LD(TM)

Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.

Vaccine·2001

Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.

International journal of immunopharmacology·2000

Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.

Anticancer research·2000

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.

Vaccine·1999

Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.

AIDS research and human retroviruses·1998

Enzyme-linked immunosorbent assay quantification of cytokine concentrations in human meningiomas.

Neurosurgery·1996

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.

The New England journal of medicine·2026

Computed tomographic Characteristics of Presumed Normal Canine Iliosacral Lymph Nodes.

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2026

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells.

Molecular therapy. Nucleic acids·2026

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.

Frontiers in immunology·2026

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.

Frontiers in immunology·2026

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.

Journal of translational medicine·2026

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.

ImmunoHorizons·2026

Related Experiment Videos

Inactivation of human T-cell lymphotropic retrovirus (HTLV-III) by LD(TM)

Related Concept Videos

Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.

Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.

Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.

Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.

Enzyme-linked immunosorbent assay quantification of cytokine concentrations in human meningiomas.

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.

Computed tomographic Characteristics of Presumed Normal Canine Iliosacral Lymph Nodes.

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells.

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.

Related Experiment Videos

Inactivation of human T-cell lymphotropic retrovirus (HTLV-III) by LD(TM)

Related Concept Videos

Related Articles